Genetic Markers Predict Who Benefits Most from GLP-1 Agonists for Weight Loss

The global burden of obesity and type 2 diabetes continues to rise, with GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide emerging as highly effective treatments for significant weight loss. However, individual responses to these medications vary widely, with some patients experiencing substantial benefits while others see minimal change or significant side effects. This variability highlights a critical need for personalized medicine approaches. This study addresses the knowledge gap of identifying specific genetic predictors that influence both the efficacy and side effect profile of GLP-1 RAs.

The study identified 5 novel genetic loci significantly associated with varying responses to GLP-1 RA treatment. Patients carrying a specific variant at SNP rs1018293 near the MC4R gene exhibited an average of 18.5% greater total body weight loss compared to those without the variant (p<0.001). Conversely, a variant at SNP rs2039485 was associated with a 2.7-fold increased risk of severe gastrointestinal side effects (nausea, vomiting) (p<0.005). Furthermore, individuals with a favorable genetic profile (presence of rs1018293 and absence of rs2039485) achieved an average of 22% weight loss, whereas those with an unfavorable profile only lost 5% of their body weight. > The most impactful finding was that a specific genetic signature, combining variants at rs1018293 and rs304958, predicted exceptional weight loss (over 25% of initial body weight) in 15% of the treated population, representing a 3.1-fold higher likelihood of achieving this outcome compared to the general cohort.